Lavipharm S.A.
I · AI Analysis
The brief
Lavipharm develops, manufactures, and distributes pharmaceutical products in cardiology, oncology-urology, central nervous system treatments, chronic pain management, and self-treatment categories [Yahoo Finance]. The company sells both prescription medicines and over-the-counter products to physicians and pharmacists in Greece and international markets [Yahoo Finance]. It also markets LIFELAB CBD products and employs 306 people [Yahoo Finance].
Lavipharm S.A. is a Greek pharmaceutical company founded in 1911 that manufactures and sells generic and specialty medicines, over-the-counter products, and CBD offerings across multiple therapeutic areas [Yahoo Finance]. The company reported trailing-twelve-month revenue of EUR 70.3M through 30 June 2026, with net income of EUR 5.8M [Yahoo Finance]. Institutional ownership is extremely low at 1.2%, while strategic or insider holders control 61.1% of shares outstanding [Yahoo Finance].
Lavipharm posted strong recent revenue growth but carries moderate leverage and trades at a high earnings multiple relative to its profitability.
Sentinellis health
Moderate concerns
5.8/10
7.5+ strong · 4.5–7.5 moderate · under 4.5 weak
Profitability
Returns on capital
Growth & momentum
Balance sheet
Cash generation
Value creation
Sentinellis calculation from the published statements — not a score reported by any data source. Each category is scored on the checks that had data; missing inputs are excluded rather than counted as failures.
Market capitalisation
EUR 257.9M
Revenue (TTM)
EUR 70.3M
Explainers
How we read these numbers
Plain-English guides · no account needed
ROIC vs WACC Explained: How to Tell If a Company Actually Creates Value
What ROIC and WACC are, how to compute both, and why the spread between them is the single most important number in fundamental investing.
ReadPiotroski F-Score Explained: A 9-Point Financial Health Check (with a Live Apple Example)
What the Piotroski F-Score is, how to calculate all 9 criteria, and how to read the result. Plain English, with a real Apple walkthrough.
ReadAltman Z-Score Explained: Predicting Bankruptcy in 5 Minutes (with Real Examples)
What the Altman Z-Score is, the exact formula, how to read the result, and which version to use for manufacturers vs tech vs private companies.
ReadPremium · Free with any account
The company trades at a P/E ratio of 44.9x with no forward earnings estimate available, leaving valuation difficult to assess and potentially vulnerable to correction if growth moderates [Yahoo Finance].
Risks
5
Opportunities
5
Red flags
3
Leadership
10
12 more findings in the full report — free with any account.
Unlock the full Lavipharm S.A. analysis
Create a free account to access the complete AI-generated report with inline citations.
- 5 risks, 5 opportunities and 3 red flags — each with its source
- 100+ financial metrics with charts and benchmarks
- Full news summaries with source links
- Executive team and compensation details
- PDF export for offline use
III · Related
You might also read
Same sector · Healthcare — or comparable health
Want this for your watchlist?